Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR)

Date
2021
Author
ALHAN, ASLIHAN
Olgun, Fatih Erkam
Demirkan, Burcu
Atas, Ali Ekber
Kilicaslan, Fethi
Altay, Hakan
Tengiz, Istemihan
Erkan, Aycan Fahri
Kilicaslan, Baris
EKİCİ, BERKAY
Yaman, Mehmet
KÜÇÜK, MURATHAN
ZOGHİ, MEHDİ
DURAKOĞLUGİL, MURTAZA EMRE
Dereli, Seckin
Yenercag, Mustafa
Yigit, Zerrin
Bas, Mehmet Memduh
KARAVELİOĞLU, YUSUF
Cakmak, Huseyin Altug
Kivrak, Tarik
Ozkan, Hakan
Altin, Cihan
Sabanoglu, Cengiz
Metadata
Show full item record
Abstract
Objective: Heart failure (HF) is a growing public health problem with high morbidity and mortality. Recently, angiotensin receptor neprilysin inhibitor (ARNi) has emerged as a promising treatment for HF with reduced ejection fraction (HFrEF). Here, we shared our experience with the use of ARNi in HFrEF from multiple centers in Turkey.
URI
http://hdl.handle.net/20.500.12627/169930
https://doi.org/10.5543/tkda.2021.63099
Collections